RhumbLine Advisers
KRYS icon

RhumbLine Advisers’s Krystal Biotech KRYS Stock Holding History

RhumbLine Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8M Sell
61,236
-6,863
-10% -$2.05M 0.02% 695
2026
Q1 		$17.6M Buy
68,099
+1,663
+3% +$443K 0.02% 771
2025
Q4 		$16.4M Sell
66,436
-4,116
-6% -$866K 0.01% 818
2025
Q3 		$12.5M Sell
70,552
-201
-0.3% -$30.1K 0.01% 979
2025
Q2 		$9.73M Buy
70,753
+2,026
+3% +$298K 0.01% 1062
2025
Q1 		$12.4M Sell
68,727
-409
-0.6% -$68.8K 0.01% 924
2024
Q4 		$10.8M Sell
69,136
-1,173
-2% -$208K 0.01% 1012
2024
Q3 		$12.8M Sell
70,309
-1,376
-2% -$265K 0.01% 948
2024
Q2 		$13.2M Buy
71,685
+39,586
+123% +$6.65M 0.01% 896
2024
Q1 		$5.71M Buy
32,099
+314
+1% +$43.6K 0.01% 1347
2023
Q4 		$3.94M Sell
31,785
-618
-2% -$68.5K ﹤0.01% 1560
2023
Q3 		$3.76M Buy
32,403
+1,388
+4% +$169K ﹤0.01% 1513
2023
Q2 		$3.64M Sell
31,015
-1,454
-4% -$148K ﹤0.01% 1574
2023
Q1 		$2.6M Buy
32,469
+635
+2% +$49.9K ﹤0.01% 1674
2022
Q4 		$2.52M Buy
31,834
+711
+2% +$52.8K ﹤0.01% 1658
2022
Q3 		$2.17M Buy
31,123
+2,638
+9% +$191K ﹤0.01% 1714
2022
Q2 		$1.87M Buy
28,485
+4,646
+19% +$289K ﹤0.01% 1796
2022
Q1 		$1.59M Buy
23,839
+2,172
+10% +$136K ﹤0.01% 1925
2021
Q4 		$1.52M Buy
21,667
+123
+0.6% +$7.16K ﹤0.01% 2025
2021
Q3 		$1.13M Buy
21,544
+860
+4% +$50.9K ﹤0.01% 2169
2021
Q2 		$1.41M Buy
20,684
+5,685
+38% +$397K ﹤0.01% 2101
2021
Q1 		$1.16M Sell
14,999
-111
-0.7% -$8.07K ﹤0.01% 2139
2020
Q4 		$907K Buy
15,110
+1,435
+10% +$71.7K ﹤0.01% 2179
2020
Q3 		$589K Sell
13,675
-1,520
-10% -$66K ﹤0.01% 2211
2020
Q2 		$629K Buy
15,195
+3,020
+25% +$145K ﹤0.01% 2244
2020
Q1 		$526K Buy
12,175
+867
+8% +$45.3K ﹤0.01% 2141
2019
Q4 		$626K Buy
11,308
+1,038
+10% +$50.9K ﹤0.01% 2273
2019
Q3 		$357K Buy
10,270
+1,614
+19% +$72.2K ﹤0.01% 2484
2019
Q2 		$349K Buy
+8,656
New +$283K ﹤0.01% 2536

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RhumbLine Advisers's KRYS Position: Q2 2026 in Review

RhumbLine Advisers reduced its Krystal Biotech (KRYS) stake by 10% in Q2 2026, selling an estimated $2.05M and leaving 61,236 shares worth $22.8M. The position accounts for 0.02% of the portfolio, ranked #695.

RhumbLine Advisers first reported a position in KRYS in Q2 2019 and has held it in 29 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • RhumbLine Advisers held 61,236 shares of Krystal Biotech worth $22.8M as of Q2 2026.
  • RhumbLine Advisers sold 6,863 Krystal Biotech shares in Q2 2026, an estimated $2.05M.
  • Krystal Biotech made up 0.02% of RhumbLine Advisers's portfolio in Q2 2026, its #695 holding.
  • RhumbLine Advisers first reported a position in Krystal Biotech in Q2 2019 and has held it in 29 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.